nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—UGT2B7—urinary bladder cancer	0.584	1	CbGaD
Dabigatran etexilate—UGT2B7—Epirubicin—urinary bladder cancer	0.0774	0.437	CbGbCtD
Dabigatran etexilate—ABCB1—Mitomycin—urinary bladder cancer	0.0503	0.284	CbGbCtD
Dabigatran etexilate—ABCB1—Gemcitabine—urinary bladder cancer	0.0145	0.0818	CbGbCtD
Dabigatran etexilate—ABCB1—Cisplatin—urinary bladder cancer	0.0105	0.0595	CbGbCtD
Dabigatran etexilate—ABCB1—Etoposide—urinary bladder cancer	0.0103	0.0584	CbGbCtD
Dabigatran etexilate—ABCB1—Doxorubicin—urinary bladder cancer	0.00705	0.0398	CbGbCtD
Dabigatran etexilate—ABCB1—Methotrexate—urinary bladder cancer	0.00683	0.0386	CbGbCtD
Dabigatran etexilate—F2—urine—urinary bladder cancer	0.00562	0.105	CbGeAlD
Dabigatran etexilate—UGT2B15—prostate gland—urinary bladder cancer	0.00368	0.0689	CbGeAlD
Dabigatran etexilate—UGT2B15—urethra—urinary bladder cancer	0.00246	0.0462	CbGeAlD
Dabigatran etexilate—CES2—prostate gland—urinary bladder cancer	0.00225	0.0421	CbGeAlD
Dabigatran etexilate—UGT2B7—prostate gland—urinary bladder cancer	0.00225	0.0421	CbGeAlD
Dabigatran etexilate—F2—prostate gland—urinary bladder cancer	0.00202	0.0378	CbGeAlD
Dabigatran etexilate—UGT2B15—female reproductive system—urinary bladder cancer	0.00201	0.0376	CbGeAlD
Dabigatran etexilate—NQO2—prostate gland—urinary bladder cancer	0.00201	0.0376	CbGeAlD
Dabigatran etexilate—CES2—seminal vesicle—urinary bladder cancer	0.0019	0.0356	CbGeAlD
Dabigatran etexilate—UGT1A9—renal system—urinary bladder cancer	0.0019	0.0356	CbGeAlD
Dabigatran etexilate—CES1—prostate gland—urinary bladder cancer	0.00185	0.0347	CbGeAlD
Dabigatran etexilate—NQO2—seminal vesicle—urinary bladder cancer	0.0017	0.0318	CbGeAlD
Dabigatran etexilate—CES2—smooth muscle tissue—urinary bladder cancer	0.00159	0.0298	CbGeAlD
Dabigatran etexilate—CES2—renal system—urinary bladder cancer	0.00153	0.0287	CbGeAlD
Dabigatran etexilate—UGT2B7—renal system—urinary bladder cancer	0.00153	0.0287	CbGeAlD
Dabigatran etexilate—CES2—urethra—urinary bladder cancer	0.00151	0.0282	CbGeAlD
Dabigatran etexilate—F2—epithelium—urinary bladder cancer	0.00148	0.0278	CbGeAlD
Dabigatran etexilate—F2—renal system—urinary bladder cancer	0.00137	0.0257	CbGeAlD
Dabigatran etexilate—NQO2—renal system—urinary bladder cancer	0.00137	0.0256	CbGeAlD
Dabigatran etexilate—NQO2—urethra—urinary bladder cancer	0.00135	0.0252	CbGeAlD
Dabigatran etexilate—UGT2B7—female reproductive system—urinary bladder cancer	0.00123	0.023	CbGeAlD
Dabigatran etexilate—CES2—female reproductive system—urinary bladder cancer	0.00123	0.023	CbGeAlD
Dabigatran etexilate—CES2—vagina—urinary bladder cancer	0.00111	0.0208	CbGeAlD
Dabigatran etexilate—F2—female reproductive system—urinary bladder cancer	0.0011	0.0206	CbGeAlD
Dabigatran etexilate—NQO2—female reproductive system—urinary bladder cancer	0.0011	0.0205	CbGeAlD
Dabigatran etexilate—CES1—female reproductive system—urinary bladder cancer	0.00101	0.0189	CbGeAlD
Dabigatran etexilate—NQO2—vagina—urinary bladder cancer	0.000992	0.0186	CbGeAlD
Dabigatran etexilate—CES2—lymph node—urinary bladder cancer	0.000718	0.0134	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—urinary bladder cancer	0.000642	0.012	CbGeAlD
Dabigatran etexilate—CES1—lymph node—urinary bladder cancer	0.000591	0.0111	CbGeAlD
Dabigatran etexilate—ABCB1—prostate gland—urinary bladder cancer	0.000434	0.00812	CbGeAlD
Dabigatran etexilate—ABCB1—seminal vesicle—urinary bladder cancer	0.000367	0.00687	CbGeAlD
Dabigatran etexilate—ABCB1—epithelium—urinary bladder cancer	0.000319	0.00597	CbGeAlD
Dabigatran etexilate—ABCB1—renal system—urinary bladder cancer	0.000296	0.00554	CbGeAlD
Dabigatran etexilate—ABCB1—urethra—urinary bladder cancer	0.00029	0.00544	CbGeAlD
Dabigatran etexilate—ABCB1—female reproductive system—urinary bladder cancer	0.000237	0.00443	CbGeAlD
Dabigatran etexilate—ABCB1—vagina—urinary bladder cancer	0.000214	0.00401	CbGeAlD
Dabigatran etexilate—ABCB1—lymph node—urinary bladder cancer	0.000139	0.00259	CbGeAlD
Dabigatran etexilate—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000126	0.00133	CcSEcCtD
Dabigatran etexilate—Chest pain—Etoposide—urinary bladder cancer	0.000126	0.00133	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000126	0.00133	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000125	0.00132	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000124	0.00131	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000124	0.00131	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000124	0.00131	CcSEcCtD
Dabigatran etexilate—Hypotension—Cisplatin—urinary bladder cancer	0.000123	0.0013	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000123	0.0013	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000122	0.00129	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000122	0.00129	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000122	0.00129	CcSEcCtD
Dabigatran etexilate—Fatigue—Gemcitabine—urinary bladder cancer	0.000122	0.00129	CcSEcCtD
Dabigatran etexilate—Gastritis—Epirubicin—urinary bladder cancer	0.000122	0.00129	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000121	0.00128	CcSEcCtD
Dabigatran etexilate—Constipation—Gemcitabine—urinary bladder cancer	0.000121	0.00128	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000121	0.00127	CcSEcCtD
Dabigatran etexilate—Asthenia—Thiotepa—urinary bladder cancer	0.00012	0.00127	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00012	0.00127	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00012	0.00127	CcSEcCtD
Dabigatran etexilate—Infection—Etoposide—urinary bladder cancer	0.00012	0.00127	CcSEcCtD
Dabigatran etexilate—Dysphagia—Epirubicin—urinary bladder cancer	0.000119	0.00126	CcSEcCtD
Dabigatran etexilate—Influenza—Epirubicin—urinary bladder cancer	0.000119	0.00126	CcSEcCtD
Dabigatran etexilate—Pruritus—Thiotepa—urinary bladder cancer	0.000119	0.00126	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000118	0.00125	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000118	0.00125	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000118	0.00124	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Cisplatin—urinary bladder cancer	0.000117	0.00124	CcSEcCtD
Dabigatran etexilate—Skin disorder—Etoposide—urinary bladder cancer	0.000117	0.00124	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000116	0.00123	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—urinary bladder cancer	0.000116	0.00122	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Thiotepa—urinary bladder cancer	0.000115	0.00121	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000115	0.00121	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—urinary bladder cancer	0.000114	0.00121	CcSEcCtD
Dabigatran etexilate—Pneumonia—Methotrexate—urinary bladder cancer	0.000114	0.0012	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000114	0.0012	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000114	0.0012	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Methotrexate—urinary bladder cancer	0.000113	0.0012	CcSEcCtD
Dabigatran etexilate—Infestation—Methotrexate—urinary bladder cancer	0.000113	0.0012	CcSEcCtD
Dabigatran etexilate—Hypotension—Etoposide—urinary bladder cancer	0.000113	0.00119	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—urinary bladder cancer	0.000113	0.00119	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000112	0.00119	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—NQO1—urinary bladder cancer	0.000112	0.00122	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL2—urinary bladder cancer	0.000111	0.00122	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Thiotepa—urinary bladder cancer	0.000111	0.00117	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000111	0.00117	CcSEcCtD
Dabigatran etexilate—Urticaria—Fluorouracil—urinary bladder cancer	0.00011	0.00117	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—urinary bladder cancer	0.00011	0.00116	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—urinary bladder cancer	0.00011	0.00116	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000109	0.00119	CbGpPWpGaD
Dabigatran etexilate—Haematuria—Methotrexate—urinary bladder cancer	0.000108	0.00114	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Etoposide—urinary bladder cancer	0.000108	0.00114	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—NCOR1—urinary bladder cancer	0.000107	0.00118	CbGpPWpGaD
Dabigatran etexilate—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000107	0.00113	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000107	0.00113	CcSEcCtD
Dabigatran etexilate—Epistaxis—Methotrexate—urinary bladder cancer	0.000107	0.00113	CcSEcCtD
Dabigatran etexilate—Vomiting—Thiotepa—urinary bladder cancer	0.000107	0.00113	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—urinary bladder cancer	0.000107	0.00113	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—urinary bladder cancer	0.000106	0.00112	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—urinary bladder cancer	0.000106	0.00112	CcSEcCtD
Dabigatran etexilate—Rash—Thiotepa—urinary bladder cancer	0.000106	0.00112	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—urinary bladder cancer	0.000106	0.00112	CcSEcCtD
Dabigatran etexilate—Dermatitis—Thiotepa—urinary bladder cancer	0.000106	0.00112	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—CYP4B1—urinary bladder cancer	0.000106	0.00116	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—GSTM1—urinary bladder cancer	0.000105	0.00115	CbGpPWpGaD
Dabigatran etexilate—Headache—Thiotepa—urinary bladder cancer	0.000105	0.00111	CcSEcCtD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.000105	0.00115	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000104	0.0011	CcSEcCtD
Dabigatran etexilate—Fatigue—Etoposide—urinary bladder cancer	0.000104	0.0011	CcSEcCtD
Dabigatran etexilate—Constipation—Etoposide—urinary bladder cancer	0.000103	0.00109	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000103	0.00109	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000102	0.00108	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000102	0.00108	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Methotrexate—urinary bladder cancer	0.000102	0.00108	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Methotrexate—urinary bladder cancer	0.000102	0.00107	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—urinary bladder cancer	0.000101	0.00111	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Gemcitabine—urinary bladder cancer	0.000101	0.00107	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000101	0.00111	CbGpPWpGaD
Dabigatran etexilate—Haematuria—Epirubicin—urinary bladder cancer	0.000101	0.00107	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—GSTP1—urinary bladder cancer	0.000101	0.0011	CbGpPWpGaD
Dabigatran etexilate—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.0001	0.00106	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.0001	0.00106	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—urinary bladder cancer	0.0001	0.00106	CcSEcCtD
Dabigatran etexilate—Pruritus—Gemcitabine—urinary bladder cancer	9.99e-05	0.00106	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—TNF—urinary bladder cancer	9.98e-05	0.00109	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SLC19A1—urinary bladder cancer	9.98e-05	0.00109	CbGpPWpGaD
Dabigatran etexilate—Nausea—Thiotepa—urinary bladder cancer	9.97e-05	0.00105	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Methotrexate—urinary bladder cancer	9.97e-05	0.00105	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—urinary bladder cancer	9.95e-05	0.00105	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.92e-05	0.00109	CbGpPWpGaD
Dabigatran etexilate—Pneumonia—Doxorubicin—urinary bladder cancer	9.87e-05	0.00104	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Etoposide—urinary bladder cancer	9.86e-05	0.00104	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	9.84e-05	0.00108	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Fluorouracil—urinary bladder cancer	9.83e-05	0.00104	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—urinary bladder cancer	9.81e-05	0.00104	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—urinary bladder cancer	9.81e-05	0.00104	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—PRSS3—urinary bladder cancer	9.72e-05	0.00106	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Cisplatin—urinary bladder cancer	9.7e-05	0.00102	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Gemcitabine—urinary bladder cancer	9.67e-05	0.00102	CcSEcCtD
Dabigatran etexilate—Urticaria—Etoposide—urinary bladder cancer	9.58e-05	0.00101	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—urinary bladder cancer	9.57e-05	0.00101	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	9.55e-05	0.00105	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Etoposide—urinary bladder cancer	9.54e-05	0.00101	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—urinary bladder cancer	9.54e-05	0.00101	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—urinary bladder cancer	9.52e-05	0.00101	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Fluorouracil—urinary bladder cancer	9.5e-05	0.001	CcSEcCtD
Dabigatran etexilate—Asthenia—Cisplatin—urinary bladder cancer	9.45e-05	0.000998	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—urinary bladder cancer	9.44e-05	0.000997	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—urinary bladder cancer	9.4e-05	0.000993	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—urinary bladder cancer	9.38e-05	0.000991	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—urinary bladder cancer	9.35e-05	0.000988	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—urinary bladder cancer	9.35e-05	0.000988	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—urinary bladder cancer	9.33e-05	0.000986	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—GSTP1—urinary bladder cancer	9.32e-05	0.00102	CbGpPWpGaD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	9.28e-05	0.00098	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—urinary bladder cancer	9.25e-05	0.000978	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—GSTM1—urinary bladder cancer	9.25e-05	0.00101	CbGpPWpGaD
Dabigatran etexilate—Angiopathy—Methotrexate—urinary bladder cancer	9.23e-05	0.000975	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—urinary bladder cancer	9.2e-05	0.000972	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—urinary bladder cancer	9.19e-05	0.000971	CcSEcCtD
Dabigatran etexilate—Dizziness—Fluorouracil—urinary bladder cancer	9.18e-05	0.00097	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—urinary bladder cancer	9.17e-05	0.000968	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—GSTM1—urinary bladder cancer	9.12e-05	0.000999	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	9.04e-05	0.00099	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Cisplatin—urinary bladder cancer	9.01e-05	0.000952	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—FGFR3—urinary bladder cancer	8.99e-05	0.000985	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Gemcitabine—urinary bladder cancer	8.98e-05	0.000949	CcSEcCtD
Dabigatran etexilate—Rash—Gemcitabine—urinary bladder cancer	8.91e-05	0.000941	CcSEcCtD
Dabigatran etexilate—Dermatitis—Gemcitabine—urinary bladder cancer	8.9e-05	0.00094	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Etoposide—urinary bladder cancer	8.89e-05	0.000939	CcSEcCtD
Dabigatran etexilate—Malnutrition—Methotrexate—urinary bladder cancer	8.85e-05	0.000935	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—urinary bladder cancer	8.85e-05	0.000935	CcSEcCtD
Dabigatran etexilate—Headache—Gemcitabine—urinary bladder cancer	8.85e-05	0.000935	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—urinary bladder cancer	8.83e-05	0.000933	CcSEcCtD
Dabigatran etexilate—Vomiting—Fluorouracil—urinary bladder cancer	8.83e-05	0.000933	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—urinary bladder cancer	8.81e-05	0.00093	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	8.78e-05	0.000962	CbGpPWpGaD
Dabigatran etexilate—Rash—Fluorouracil—urinary bladder cancer	8.76e-05	0.000925	CcSEcCtD
Dabigatran etexilate—Dermatitis—Fluorouracil—urinary bladder cancer	8.75e-05	0.000924	CcSEcCtD
Dabigatran etexilate—Headache—Fluorouracil—urinary bladder cancer	8.7e-05	0.000919	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	8.7e-05	0.000919	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—urinary bladder cancer	8.68e-05	0.000917	CcSEcCtD
Dabigatran etexilate—Asthenia—Etoposide—urinary bladder cancer	8.65e-05	0.000914	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	8.65e-05	0.000914	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—urinary bladder cancer	8.64e-05	0.000912	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—urinary bladder cancer	8.63e-05	0.000912	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	8.62e-05	0.000945	CbGpPWpGaD
Dabigatran etexilate—Immune system disorder—Epirubicin—urinary bladder cancer	8.6e-05	0.000908	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—urinary bladder cancer	8.58e-05	0.000906	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—GSTM1—urinary bladder cancer	8.57e-05	0.000938	CbGpPWpGaD
Dabigatran etexilate—Back pain—Methotrexate—urinary bladder cancer	8.56e-05	0.000905	CcSEcCtD
Dabigatran etexilate—Pruritus—Etoposide—urinary bladder cancer	8.53e-05	0.000902	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—CDX2—urinary bladder cancer	8.43e-05	0.000923	CbGpPWpGaD
Dabigatran etexilate—Nausea—Gemcitabine—urinary bladder cancer	8.39e-05	0.000887	CcSEcCtD
Dabigatran etexilate—Vomiting—Cisplatin—urinary bladder cancer	8.37e-05	0.000884	CcSEcCtD
Dabigatran etexilate—Rash—Cisplatin—urinary bladder cancer	8.3e-05	0.000877	CcSEcCtD
Dabigatran etexilate—Dermatitis—Cisplatin—urinary bladder cancer	8.29e-05	0.000876	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—urinary bladder cancer	8.29e-05	0.000875	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Etoposide—urinary bladder cancer	8.25e-05	0.000872	CcSEcCtD
Dabigatran etexilate—Nausea—Fluorouracil—urinary bladder cancer	8.25e-05	0.000872	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	8.21e-05	0.0009	CbGpPWpGaD
Dabigatran etexilate—Anaemia—Methotrexate—urinary bladder cancer	8.18e-05	0.000865	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—GSTP1—urinary bladder cancer	8.18e-05	0.000895	CbGpPWpGaD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—urinary bladder cancer	8.17e-05	0.000863	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—urinary bladder cancer	8.16e-05	0.000863	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—TNF—urinary bladder cancer	8.12e-05	0.000889	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.06e-05	0.000883	CbGpPWpGaD
Dabigatran etexilate—Back pain—Epirubicin—urinary bladder cancer	8.01e-05	0.000847	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—urinary bladder cancer	7.99e-05	0.000844	CcSEcCtD
Dabigatran etexilate—Dizziness—Etoposide—urinary bladder cancer	7.98e-05	0.000843	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—urinary bladder cancer	7.95e-05	0.00084	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.94e-05	0.000839	CcSEcCtD
Dabigatran etexilate—Nausea—Cisplatin—urinary bladder cancer	7.82e-05	0.000826	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—TYMP—urinary bladder cancer	7.77e-05	0.000851	CbGpPWpGaD
Dabigatran etexilate—Cough—Methotrexate—urinary bladder cancer	7.73e-05	0.000816	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—PPARG—urinary bladder cancer	7.7e-05	0.000843	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Etoposide—urinary bladder cancer	7.67e-05	0.00081	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—urinary bladder cancer	7.67e-05	0.00081	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—urinary bladder cancer	7.66e-05	0.000809	CcSEcCtD
Dabigatran etexilate—Rash—Etoposide—urinary bladder cancer	7.61e-05	0.000804	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etoposide—urinary bladder cancer	7.6e-05	0.000803	CcSEcCtD
Dabigatran etexilate—Headache—Etoposide—urinary bladder cancer	7.56e-05	0.000798	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—urinary bladder cancer	7.55e-05	0.000798	CcSEcCtD
Dabigatran etexilate—Chest pain—Methotrexate—urinary bladder cancer	7.54e-05	0.000796	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—urinary bladder cancer	7.54e-05	0.000796	CcSEcCtD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	7.54e-05	0.000825	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—GSTM1—urinary bladder cancer	7.51e-05	0.000823	CbGpPWpGaD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	7.49e-05	0.000791	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—urinary bladder cancer	7.43e-05	0.000785	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—urinary bladder cancer	7.42e-05	0.000783	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.41e-05	0.000812	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—CREBBP—urinary bladder cancer	7.4e-05	0.00081	CbGpPWpGaD
Dabigatran etexilate—Palpitations—Epirubicin—urinary bladder cancer	7.32e-05	0.000774	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—urinary bladder cancer	7.28e-05	0.000769	CcSEcCtD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	7.25e-05	0.000794	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	7.24e-05	0.000793	CbGpPWpGaD
Dabigatran etexilate—Cough—Epirubicin—urinary bladder cancer	7.23e-05	0.000764	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.23e-05	0.000763	CcSEcCtD
Dabigatran etexilate—Infection—Methotrexate—urinary bladder cancer	7.18e-05	0.000758	CcSEcCtD
Dabigatran etexilate—Nausea—Etoposide—urinary bladder cancer	7.17e-05	0.000757	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—TP53—urinary bladder cancer	7.16e-05	0.000784	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Epirubicin—urinary bladder cancer	7.15e-05	0.000756	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methotrexate—urinary bladder cancer	7.09e-05	0.000749	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—urinary bladder cancer	7.09e-05	0.000749	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.07e-05	0.000747	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—urinary bladder cancer	7.05e-05	0.000745	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—urinary bladder cancer	7.05e-05	0.000745	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—SRC—urinary bladder cancer	7.03e-05	0.00077	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—NAT2—urinary bladder cancer	7.03e-05	0.00077	CbGpPWpGaD
Dabigatran etexilate—Skin disorder—Methotrexate—urinary bladder cancer	7.02e-05	0.000741	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.01e-05	0.00074	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—RHOA—urinary bladder cancer	6.93e-05	0.000759	CbGpPWpGaD
Dabigatran etexilate—Syncope—Doxorubicin—urinary bladder cancer	6.87e-05	0.000726	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—urinary bladder cancer	6.77e-05	0.000716	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.76e-05	0.000714	CcSEcCtD
Dabigatran etexilate—Hypotension—Methotrexate—urinary bladder cancer	6.75e-05	0.000713	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.74e-05	0.000712	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	6.73e-05	0.000737	CbGpPWpGaD
Dabigatran etexilate—Infection—Epirubicin—urinary bladder cancer	6.72e-05	0.00071	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—urinary bladder cancer	6.69e-05	0.000707	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—urinary bladder cancer	6.65e-05	0.000703	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—urinary bladder cancer	6.63e-05	0.000701	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.62e-05	0.000699	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—urinary bladder cancer	6.62e-05	0.000699	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.58e-05	0.000695	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—urinary bladder cancer	6.57e-05	0.000694	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	6.54e-05	0.000716	CbGpPWpGaD
Dabigatran etexilate—Arthralgia—Doxorubicin—urinary bladder cancer	6.53e-05	0.00069	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—urinary bladder cancer	6.53e-05	0.00069	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6.48e-05	0.000685	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—TNF—urinary bladder cancer	6.45e-05	0.000706	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Methotrexate—urinary bladder cancer	6.44e-05	0.000681	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methotrexate—urinary bladder cancer	6.36e-05	0.000672	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—urinary bladder cancer	6.32e-05	0.000668	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.26e-05	0.000661	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.24e-05	0.000659	CcSEcCtD
Dabigatran etexilate—Fatigue—Methotrexate—urinary bladder cancer	6.23e-05	0.000658	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—urinary bladder cancer	6.22e-05	0.000657	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—GSTZ1—urinary bladder cancer	6.16e-05	0.000675	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.16e-05	0.000651	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—urinary bladder cancer	6.16e-05	0.00065	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.14e-05	0.000648	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.13e-05	0.000647	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—urinary bladder cancer	6.08e-05	0.000642	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—RRM2—urinary bladder cancer	6.07e-05	0.000665	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Epirubicin—urinary bladder cancer	6.03e-05	0.000637	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—urinary bladder cancer	5.95e-05	0.000629	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.91e-05	0.000624	CcSEcCtD
Dabigatran etexilate—Hypotension—Doxorubicin—urinary bladder cancer	5.85e-05	0.000618	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—GSTO2—urinary bladder cancer	5.84e-05	0.00064	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NAT1—urinary bladder cancer	5.84e-05	0.00064	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.84e-05	0.000617	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—urinary bladder cancer	5.83e-05	0.000616	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—KRAS—urinary bladder cancer	5.82e-05	0.000638	CbGpPWpGaD
Dabigatran etexilate—Constipation—Epirubicin—urinary bladder cancer	5.78e-05	0.000611	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	5.76e-05	0.000631	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Methotrexate—urinary bladder cancer	5.74e-05	0.000606	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—urinary bladder cancer	5.71e-05	0.000603	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.7e-05	0.000602	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—HPGDS—urinary bladder cancer	5.62e-05	0.000615	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ENO2—urinary bladder cancer	5.62e-05	0.000615	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Doxorubicin—urinary bladder cancer	5.58e-05	0.000589	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.53e-05	0.000584	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	5.52e-05	0.000604	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Doxorubicin—urinary bladder cancer	5.51e-05	0.000582	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—GSTT1—urinary bladder cancer	5.45e-05	0.000597	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.4e-05	0.000571	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—urinary bladder cancer	5.39e-05	0.00057	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—urinary bladder cancer	5.37e-05	0.000568	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—urinary bladder cancer	5.35e-05	0.000565	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—urinary bladder cancer	5.35e-05	0.000565	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Methotrexate—urinary bladder cancer	5.32e-05	0.000562	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—IGFBP3—urinary bladder cancer	5.29e-05	0.00058	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	5.19e-05	0.000569	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Methotrexate—urinary bladder cancer	5.18e-05	0.000548	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	5.13e-05	0.000562	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.12e-05	0.000541	CcSEcCtD
Dabigatran etexilate—Pruritus—Methotrexate—urinary bladder cancer	5.11e-05	0.00054	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	5.11e-05	0.000559	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	5.1e-05	0.000558	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	5.05e-05	0.000553	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—EP300—urinary bladder cancer	5.04e-05	0.000552	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTZ1—urinary bladder cancer	5.01e-05	0.000549	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	5.01e-05	0.000548	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	4.99e-05	0.000546	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Epirubicin—urinary bladder cancer	4.98e-05	0.000526	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—urinary bladder cancer	4.97e-05	0.000525	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—HRAS—urinary bladder cancer	4.95e-05	0.000542	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Doxorubicin—urinary bladder cancer	4.95e-05	0.000523	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Methotrexate—urinary bladder cancer	4.94e-05	0.000522	CcSEcCtD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	4.93e-05	0.00054	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IFNA2—urinary bladder cancer	4.92e-05	0.000539	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Epirubicin—urinary bladder cancer	4.85e-05	0.000513	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—CYP4B1—urinary bladder cancer	4.81e-05	0.000527	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Epirubicin—urinary bladder cancer	4.78e-05	0.000505	CcSEcCtD
Dabigatran etexilate—Dizziness—Methotrexate—urinary bladder cancer	4.78e-05	0.000505	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—GSTO2—urinary bladder cancer	4.75e-05	0.00052	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NAT1—urinary bladder cancer	4.75e-05	0.00052	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.67e-05	0.000511	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	4.65e-05	0.000509	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Epirubicin—urinary bladder cancer	4.63e-05	0.000489	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.61e-05	0.000487	CcSEcCtD
Dabigatran etexilate—Vomiting—Methotrexate—urinary bladder cancer	4.59e-05	0.000485	CcSEcCtD
Dabigatran etexilate—Rash—Methotrexate—urinary bladder cancer	4.56e-05	0.000481	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—urinary bladder cancer	4.55e-05	0.000481	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—SLC19A1—urinary bladder cancer	4.54e-05	0.000498	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—NQO1—urinary bladder cancer	4.53e-05	0.000496	CbGpPWpGaD
Dabigatran etexilate—Headache—Methotrexate—urinary bladder cancer	4.53e-05	0.000478	CcSEcCtD
Dabigatran etexilate—Asthenia—Doxorubicin—urinary bladder cancer	4.49e-05	0.000474	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—urinary bladder cancer	4.47e-05	0.000472	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EGFR—urinary bladder cancer	4.44e-05	0.000487	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PRSS3—urinary bladder cancer	4.43e-05	0.000485	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Doxorubicin—urinary bladder cancer	4.43e-05	0.000468	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—UGT2B7—urinary bladder cancer	4.34e-05	0.000476	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Epirubicin—urinary bladder cancer	4.3e-05	0.000454	CcSEcCtD
Dabigatran etexilate—Nausea—Methotrexate—urinary bladder cancer	4.29e-05	0.000453	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—urinary bladder cancer	4.28e-05	0.000452	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—urinary bladder cancer	4.26e-05	0.00045	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—urinary bladder cancer	4.26e-05	0.00045	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	4.24e-05	0.000464	CbGpPWpGaD
Dabigatran etexilate—Headache—Epirubicin—urinary bladder cancer	4.24e-05	0.000448	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—urinary bladder cancer	4.2e-05	0.00046	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Doxorubicin—urinary bladder cancer	4.14e-05	0.000437	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	4.11e-05	0.00045	CbGpPWpGaD
Dabigatran etexilate—Nausea—Epirubicin—urinary bladder cancer	4.02e-05	0.000424	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—urinary bladder cancer	3.98e-05	0.00042	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—urinary bladder cancer	3.94e-05	0.000417	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—urinary bladder cancer	3.94e-05	0.000416	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—urinary bladder cancer	3.92e-05	0.000414	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—CYP4B1—urinary bladder cancer	3.91e-05	0.000428	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	3.85e-05	0.000421	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HDAC4—urinary bladder cancer	3.79e-05	0.000415	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTP1—urinary bladder cancer	3.78e-05	0.000414	CbGpPWpGaD
Dabigatran etexilate—Nausea—Doxorubicin—urinary bladder cancer	3.72e-05	0.000393	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	3.7e-05	0.000405	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC19A1—urinary bladder cancer	3.69e-05	0.000404	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PRSS3—urinary bladder cancer	3.6e-05	0.000394	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMP—urinary bladder cancer	3.54e-05	0.000388	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TYMS—urinary bladder cancer	3.51e-05	0.000385	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	3.51e-05	0.000385	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PLAU—urinary bladder cancer	3.49e-05	0.000382	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	3.48e-05	0.000381	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—NCOR1—urinary bladder cancer	3.47e-05	0.00038	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTM1—urinary bladder cancer	3.47e-05	0.00038	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	3.4e-05	0.000372	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.36e-05	0.000368	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.36e-05	0.000368	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	3.36e-05	0.000368	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GPX1—urinary bladder cancer	3.32e-05	0.000364	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	3.31e-05	0.000363	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.26e-05	0.000358	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ERCC2—urinary bladder cancer	3.26e-05	0.000357	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.21e-05	0.000351	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NAT2—urinary bladder cancer	3.2e-05	0.000351	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GLI1—urinary bladder cancer	3.17e-05	0.000348	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	3.13e-05	0.000343	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—MTHFR—urinary bladder cancer	3.07e-05	0.000336	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.89e-05	0.000316	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—CREBBP—urinary bladder cancer	2.88e-05	0.000315	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMP—urinary bladder cancer	2.88e-05	0.000315	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IGF1—urinary bladder cancer	2.84e-05	0.000311	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.84e-05	0.000311	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—RRM2—urinary bladder cancer	2.76e-05	0.000303	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.76e-05	0.000303	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.74e-05	0.0003	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	2.66e-05	0.000291	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—RHOA—urinary bladder cancer	2.6e-05	0.000285	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NAT2—urinary bladder cancer	2.6e-05	0.000285	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ENO2—urinary bladder cancer	2.56e-05	0.00028	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HPGDS—urinary bladder cancer	2.56e-05	0.00028	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL8—urinary bladder cancer	2.56e-05	0.00028	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.51e-05	0.000275	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.5e-05	0.000274	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.49e-05	0.000273	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARG—urinary bladder cancer	2.49e-05	0.000272	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTT1—urinary bladder cancer	2.48e-05	0.000272	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.44e-05	0.000268	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CREBBP—urinary bladder cancer	2.39e-05	0.000262	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.3e-05	0.000252	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—RRM2—urinary bladder cancer	2.25e-05	0.000246	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGF1—urinary bladder cancer	2.24e-05	0.000245	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—urinary bladder cancer	2.19e-05	0.000239	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.18e-05	0.000239	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.18e-05	0.000239	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.18e-05	0.000239	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RBX1—urinary bladder cancer	2.18e-05	0.000238	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.15e-05	0.000236	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ENO2—urinary bladder cancer	2.08e-05	0.000228	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HPGDS—urinary bladder cancer	2.08e-05	0.000228	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.07e-05	0.000226	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NQO1—urinary bladder cancer	2.06e-05	0.000226	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TSC1—urinary bladder cancer	2.05e-05	0.000224	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTT1—urinary bladder cancer	2.02e-05	0.000221	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.99e-05	0.000218	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.99e-05	0.000218	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—EP300—urinary bladder cancer	1.96e-05	0.000215	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—urinary bladder cancer	1.96e-05	0.000214	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JAG1—urinary bladder cancer	1.95e-05	0.000213	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SRC—urinary bladder cancer	1.91e-05	0.000209	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.85e-05	0.000203	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.83e-05	0.0002	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CXCL8—urinary bladder cancer	1.8e-05	0.000197	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.79e-05	0.000196	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.79e-05	0.000196	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTP1—urinary bladder cancer	1.72e-05	0.000188	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—urinary bladder cancer	1.71e-05	0.000187	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.69e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NQO1—urinary bladder cancer	1.68e-05	0.000184	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.65e-05	0.000181	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—RHOA—urinary bladder cancer	1.65e-05	0.00018	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—EP300—urinary bladder cancer	1.63e-05	0.000178	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.63e-05	0.000178	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.61e-05	0.000177	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMS—urinary bladder cancer	1.6e-05	0.000175	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTM1—urinary bladder cancer	1.58e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NCOR1—urinary bladder cancer	1.58e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—urinary bladder cancer	1.58e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—S100B—urinary bladder cancer	1.58e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.56e-05	0.000171	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.56e-05	0.000171	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GPX1—urinary bladder cancer	1.51e-05	0.000166	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—RHOA—urinary bladder cancer	1.49e-05	0.000164	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ERCC2—urinary bladder cancer	1.49e-05	0.000163	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.49e-05	0.000163	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.45e-05	0.000158	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.44e-05	0.000158	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.42e-05	0.000155	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NCOR1—urinary bladder cancer	1.42e-05	0.000155	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—urinary bladder cancer	1.4e-05	0.000154	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	1.4e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—urinary bladder cancer	1.4e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—urinary bladder cancer	1.38e-05	0.000151	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.35e-05	0.000148	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—urinary bladder cancer	1.34e-05	0.000147	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.32e-05	0.000145	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.31e-05	0.000144	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMS—urinary bladder cancer	1.3e-05	0.000142	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.3e-05	0.000142	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	1.28e-05	0.000141	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	1.28e-05	0.000141	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.27e-05	0.000139	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—urinary bladder cancer	1.25e-05	0.000137	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—urinary bladder cancer	1.25e-05	0.000137	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GPX1—urinary bladder cancer	1.23e-05	0.000135	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	1.21e-05	0.000132	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.21e-05	0.000132	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.2e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.19e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGFR3—urinary bladder cancer	1.15e-05	0.000126	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	0.000124	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARG—urinary bladder cancer	1.13e-05	0.000124	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—urinary bladder cancer	1.11e-05	0.000122	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	1.09e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.06e-05	0.000116	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.03e-05	0.000113	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CREBBP—urinary bladder cancer	9.76e-06	0.000107	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1—urinary bladder cancer	9.64e-06	0.000106	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—urinary bladder cancer	9.59e-06	0.000105	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HPGDS—urinary bladder cancer	9.54e-06	0.000104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO2—urinary bladder cancer	9.54e-06	0.000104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTT1—urinary bladder cancer	9.25e-06	0.000101	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARG—urinary bladder cancer	9.21e-06	0.000101	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—urinary bladder cancer	9.06e-06	9.92e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	8.91e-06	9.76e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	8.85e-06	9.69e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RHOA—urinary bladder cancer	8.83e-06	9.67e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.66e-06	9.49e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—urinary bladder cancer	8.17e-06	8.95e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—urinary bladder cancer	7.77e-06	8.51e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL8—urinary bladder cancer	7.75e-06	8.49e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—urinary bladder cancer	7.7e-06	8.43e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NQO1—urinary bladder cancer	7.69e-06	8.42e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—EP300—urinary bladder cancer	7.41e-06	8.12e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—urinary bladder cancer	7.41e-06	8.11e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	7.24e-06	7.93e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—urinary bladder cancer	7.22e-06	7.91e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—urinary bladder cancer	7.01e-06	7.68e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.99e-06	7.65e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—urinary bladder cancer	6.97e-06	7.63e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EP300—urinary bladder cancer	6.65e-06	7.28e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SRC—urinary bladder cancer	6.46e-06	7.08e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTP1—urinary bladder cancer	6.41e-06	7.03e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—urinary bladder cancer	6.32e-06	6.92e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—EP300—urinary bladder cancer	6.02e-06	6.6e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMS—urinary bladder cancer	5.96e-06	6.53e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.89e-06	6.46e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.89e-06	6.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—urinary bladder cancer	5.79e-06	6.34e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—urinary bladder cancer	5.67e-06	6.21e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPX1—urinary bladder cancer	5.64e-06	6.18e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ERCC2—urinary bladder cancer	5.54e-06	6.07e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—urinary bladder cancer	5.35e-06	5.86e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—urinary bladder cancer	5.21e-06	5.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—urinary bladder cancer	4.76e-06	5.21e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—urinary bladder cancer	4.55e-06	4.98e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.22e-06	4.63e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.06e-06	4.44e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.32e-06	3.64e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.9e-06	3.17e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EP300—urinary bladder cancer	2.76e-06	3.03e-05	CbGpPWpGaD
